RecruitingPHASE1, PHASE2NCT06594679

A Study of Niraparib in Combination With Abemaciclib for Late Line Treatment of Ovarian Cancer (NICHOL TRIAL)

Studying Malignant epithelial tumor of ovary

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Intervention
Niraparib Tosylate Monohydrate(drug)
Enrollment
73 target
Eligibility
18 years · FEMALE
Timeline
20242027

Study locations (1)

Collaborators

GlaxoSmithKline · Eli Lilly and Company

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT06594679 on ClinicalTrials.gov

Other trials for Malignant epithelial tumor of ovary

Additional recruiting or active studies for the same condition.

See all trials for Malignant epithelial tumor of ovary

← Back to all trials